Pacer BioThreat Strategy ETF
VIRS
VIRS was delisted on the 10th of October, 2024.
4 hedge funds and large institutions have $1.12M invested in Pacer BioThreat Strategy ETF in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
11% more capital invested
Capital invested by funds: $1.01M → $1.12M (+$111K)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
33% less funds holding
Funds holding: 6 → 4 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$191K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$77.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$132K |
| 2 |
Rockefeller Capital Management
New York
|
-$39K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$24.7K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$28 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $478K | +$77.6K | +2,707 | +20% |
|
|
2
Osaic Holdings
Scottsdale,
Arizona
| $369K | -$24.7K | -863 | -6% |
|
|
3
Royal Bank of Canada
Toronto,
Ontario, Canada
| $271K | +$191K | +6,646 | +256% |
|
|
4
UBS Group
Zurich,
Switzerland
| $234 | -$132K | -4,616 | -100% |
|
|
5
Rockefeller Capital Management
New York
| – | -$39K | -1,403 | Closed |
|
|
6
Fidelity Investments
Boston,
Massachusetts
| – | -$28 | -1 | Closed |
|
VIRS Hedge Fund Activity: Q1 2023 in Review
4 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Pacer BioThreat Strategy ETF (VIRS) for Q1 2023, worth a combined $1.12M — up 11% from $1.01M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of VIRS and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Royal Bank of Canada, adding an estimated $191K. The largest seller was UBS Group, cutting an estimated $132K.
- 4 institutional investors held Pacer BioThreat Strategy ETF (VIRS) as of Q1 2023, down from 6 in Q4 2022.
- Funds reported $1.12M of Pacer BioThreat Strategy ETF stock for Q1 2023, up 11% quarter-over-quarter.
- 0 funds opened new Pacer BioThreat Strategy ETF positions in Q1 2023 and 2 closed out, a net change of -2 holders.
- The largest Pacer BioThreat Strategy ETF buyer in Q1 2023 was Royal Bank of Canada, an estimated $191K added.
- The largest Pacer BioThreat Strategy ETF seller in Q1 2023 was UBS Group, an estimated $132K sold.
Based on aggregated 13F filings for Q1 2023.